​

Regeneron Pharmaceuticals (REGN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

REGN Stock Forecast

Regeneron Pharmaceuticals (REGN) stock forecast, based on 45 Wall Street analysts, predicts a 12-month average price target of $1,039.60, with a high of $1,195.00 and a low of $880.00. This represents a 84.60% increase from the last price of $563.16.

$550 $680 $810 $940 $1 $1 High: $1195 Avg: $1039.6 Low: $880 Last Closed Price: $563.16

REGN Stock Rating

Regeneron Pharmaceuticals stock's rating consensus is Buy, based on 45 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 34 Buy (75.56%), 11 Hold (24.44%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 45 11 34 0 Strong Sell Sell Hold Buy Strong Buy

REGN Price Target Upside V Benchmarks

TypeNameUpside
StockRegeneron Pharmaceuticals84.60%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts-128
Avg Price Target-$903.00$1.14K
Last Closing Price$563.16$563.16$563.16
Upside/Downside-60.35%103.15%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 257126-126
Mar, 257127-127
Feb, 256118-126
Jan, 257128-128
Dec, 247127-127
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 14, 2025BMO Capital$903.00$666.8735.41%60.35%
Nov 01, 2024Evan David SeigermanBMO Capital$1.19K$843.6041.06%111.31%
Nov 01, 2024Christopher RaymondPiper Sandler$1.20K$843.6041.65%112.20%
Nov 01, 2024Andrew BerensLeerink Partners$880.00$843.604.31%56.26%
Oct 31, 2024Cory KasimovEvercore ISI$1.17K$838.2039.58%107.76%
Oct 24, 2024Cory KasimovEvercore ISI$1.18K$941.3924.82%108.64%
Oct 23, 2024Mohit BansalWells Fargo$1.05K$962.349.11%86.45%
Sep 24, 2024Thomas KleeTruist Financial$1.20K$1.09K9.89%113.08%
Sep 24, 2024David RisingerLeerink Partners$1.08K$1.09K-1.37%91.24%
Sep 24, 2024Brian SkorneyRobert W. Baird$940.00$1.09K-13.92%66.92%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 13, 2024CitigroupNeutralinitialise
Nov 01, 2024Leerink PartnersMarket PerformMarket Performhold
Oct 29, 2024Piper SandlerOverweightOverweighthold
Oct 24, 2024Evercore ISIOutperformOutperformhold
Oct 23, 2024SusquehannaNeutralNeutralhold
Oct 23, 2024Cowen & Co.BuyBuyhold
Oct 23, 2024Wells FargoOverweightOverweighthold
Oct 04, 2024Wells FargoMarket PerformMarket Performhold
Sep 27, 2024Cowen & Co.BuyBuyhold
Sep 25, 2024Morgan StanleyOverweightOverweighthold

Financial Forecast

EPS Forecast

$25 $36 $47 $58 $69 $80 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$32.65$76.40$40.51$37.05$40.90----
Avg Forecast$30.33$71.52$42.60$42.62$45.02$44.51$48.41$56.23$61.14
High Forecast$31.59$74.49$45.65$43.60$47.01$52.39$60.93$71.36$66.97
Low Forecast$28.62$67.49$40.10$39.84$43.54$34.72$38.38$43.10$56.27
Surprise %7.65%6.82%-4.91%-13.07%-9.15%----

Revenue Forecast

$5B $8B $11B $14B $17B $20B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$8.50B$16.07B$12.17B$13.12B$14.20B----
Avg Forecast$8.50B$15.70B$11.86B$12.94B$14.18B$14.63B$15.52B$17.22B$18.20B
High Forecast$8.77B$16.20B$12.52B$13.07B$14.49B$15.28B$15.58B$17.22B$19.53B
Low Forecast$8.13B$15.02B$11.33B$12.65B$14.04B$13.90B$15.46B$17.21B$17.08B
Surprise %0.00%2.39%2.62%1.37%0.15%----

Net Income Forecast

$2B $3B $5B $6B $8B $9B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.51B$8.08B$4.34B$3.95B$4.41B----
Avg Forecast$2.99B$7.29B$4.49B$3.95B$5.15B$4.36B$4.65B$5.30B$6.95B
High Forecast$3.59B$8.75B$5.39B$4.74B$5.34B$5.96B$6.93B$8.11B$7.61B
Low Forecast$2.39B$5.83B$3.59B$3.16B$4.95B$3.95B$4.36B$4.90B$6.40B
Surprise %17.57%10.75%-3.36%--14.28%----

REGN Forecast FAQ

Is Regeneron Pharmaceuticals stock a buy?

Regeneron Pharmaceuticals stock has a consensus rating of Buy, based on 45 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 34 Buy, 11 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Regeneron Pharmaceuticals is a favorable investment for most analysts.

What is Regeneron Pharmaceuticals's price target?

Regeneron Pharmaceuticals's price target, set by 45 Wall Street analysts, averages $1.04K over the next 12 months. The price target range spans from $880 at the low end to $1.2K at the high end, suggesting a potential 84.60% change from the previous closing price of $563.16.

How does Regeneron Pharmaceuticals stock forecast compare to its benchmarks?

Regeneron Pharmaceuticals's stock forecast shows a 84.60% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and underperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Regeneron Pharmaceuticals over the past three months?

  • April 2025: 26.92% Strong Buy, 46.15% Buy, 23.08% Hold, 0% Sell, 3.85% Strong Sell.
  • March 2025: 25.93% Strong Buy, 44.44% Buy, 25.93% Hold, 0% Sell, 3.70% Strong Sell.
  • February 2025: 23.08% Strong Buy, 42.31% Buy, 30.77% Hold, 0% Sell, 3.85% Strong Sell.

What is Regeneron Pharmaceuticals’s EPS forecast?

Regeneron Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $44.51, marking a 8.83% increase from the reported $40.9 in 2024. Estimates for the following years are $48.41 in 2026, $56.23 in 2027, and $61.14 in 2028.

What is Regeneron Pharmaceuticals’s revenue forecast?

Regeneron Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $14.63B, reflecting a 3.00% increase from the reported $14.2B in 2024. The forecast for 2026 is $15.52B, followed by $17.22B for 2027, and $18.2B for 2028.

What is Regeneron Pharmaceuticals’s net income forecast?

Regeneron Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $4.36B, representing a -1.23% decrease from the reported $4.41B in 2024. Projections indicate $4.65B in 2026, $5.3B in 2027, and $6.95B in 2028.